# Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

> **NCT04417660** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Thymic Epithelial Tumor
- Recurrent Thymoma
- Thymic Cancer

## Interventions

- **DRUG:** M7824

## Key facts

- **NCT ID:** NCT04417660
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-26
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417660, "Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04417660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*